| abstract |
Provided are a drug that inhibits tumor angiogenesis derived from tumor stem cells, and a therapeutic drug for VEGF inhibitor-resistant cancer. An antipsychotic agent, particularly a tumor stem cell-derived angiogenesis inhibitor comprising at least one antipsychotic agent selected from a selective serotonin reuptake inhibitor (SSRI) or a tricyclic antidepressant, in particular the VEGF pathway The tumor stem detail-derived angiogenesis inhibitor for the treatment of inhibitor-resistant cancer, and the cancer stem drug comprising a combination of the tumor stem cell-derived angiogenesis inhibitor and a VEGF pathway inhibitor. [Selection figure] None |